Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy

Area of Science:

• Oncology
• Immunology
• Biomedical Engineering

Background:

• Melanoma, the deadliest skin cancer, has high mortality despite immunotherapy advances.
• Limitations in melanoma immunotherapy include low patient response rates and side effects.
• The immunosuppressive tumor microenvironment (iTME) and tumor heterogeneity impede effective treatment.

Purpose of the Study:

• To clarify how stimuli-responsive drug delivery systems (DDSs) enhance melanoma immunotherapy.
• To guide the use of DDSs as therapeutic agents for melanoma.
• To review the categorization, design, and immune-enhancing pathways of these DDSs.

Main Methods:

• Review of stimuli-responsive drug delivery systems (DDSs) designed for melanoma.
• Analysis of how DDSs exploit tumor microenvironment (TME) characteristics (acidity, hypoxia, proteases).
• Examination of immune-enhancing pathways activated by DDSs in melanoma.

Main Results:

• Stimuli-responsive DDSs can be designed to target specific TME features.
• These DDSs can modulate the immunosuppressive TME to improve immune cell function.
• Exploiting TME characteristics offers a strategy to enhance antitumor immune responses.

Conclusions:

• Stimuli-responsive DDSs represent a promising approach to improve melanoma immunotherapy efficacy.
• Further research into DDS design and immune-enhancing pathways is crucial.
• Addressing challenges and exploring future prospects will optimize DDS application in melanoma treatment.